Clinical Aspects of Melatonin Intervention in Alzheimer’s Disease Progression

Departamento de Docencia e Investigación, Facultad de Ciencias Médicas, Pontificia Universidad Católica Argentina, Buenos Aires, Argentina.
DNA research: an international journal for rapid publication of reports on genes and genomes (Impact Factor: 2.35). 09/2010; 8(3):218-27. DOI: 10.2174/157015910792246209
Source: PubMed

ABSTRACT Melatonin secretion decreases in Alzheimer´s disease (AD) and this decrease has been postulated as responsible for the circadian disorganization, decrease in sleep efficiency and impaired cognitive function seen in those patients. Half of severely ill AD patients develop chronobiological day-night rhythm disturbances like an agitated behavior during the evening hours (so-called "sundowning"). Melatonin replacement has been shown effective to treat sundowning and other sleep wake disorders in AD patients. The antioxidant, mitochondrial and antiamyloidogenic effects of melatonin indicate its potentiality to interfere with the onset of the disease. This is of particularly importance in mild cognitive impairment (MCI), an etiologically heterogeneous syndrome that precedes dementia. The aim of this manuscript was to assess published evidence of the efficacy of melatonin to treat AD and MCI patients. PubMed was searched using Entrez for articles including clinical trials and published up to 15 January 2010. Search terms were "Alzheimer" and "melatonin". Full publications were obtained and references were checked for additional material where appropriate. Only clinical studies with empirical treatment data were reviewed. The analysis of published evidence made it possible to postulate melatonin as a useful ad-on therapeutic tool in MCI. In the case of AD, larger randomized controlled trials are necessary to yield evidence of effectiveness (i.e. clinical and subjective relevance) before melatonin´s use can be advocated.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Around nineteenth century, some preliminary studies indicated that plants may possess melatonin (Mel; Kolár et al., 1995), but clear-cut indications that the plants are having Mel were supported by scientists later during 1995 (Dubbels et al., 1995). However, the existence of phyto-melatonin was reported by scientists in micro- and macro-alga (Balzer et al., 1998), particularly in red alga (Rhodophyta, Lorenz and Lüning, 1998), metazoans (Hardeland, 1999), and other photoautotrophic microorganisms (Hardeland and Poeggeler, 2003). Among the other plant groups, the existence of Mel is still controversial and needs further proof. Phyto-melatonin is now accepted to be present only in angiosperms, in their different parts like fruits, seeds, etc., including some medicinal herbs (Reiter et al., 2007). The reason behind this fact is mainly the lack of specific molecular and biochemical approaches to detect the same in plants other than angiosperms.
    Melatonin: Therapeutic Value and Neuroprotection, Edited by Siebel Susan et al, 09/2014: chapter Phyto-Melatonin A Novel Therapeutic Aspect of Melatonin in Nature’s Way: pages 515-522; Taylor and Francis., ISBN: 9781482220094
  • [Show abstract] [Hide abstract]
    ABSTRACT: Circadian rhythms are physiological and behavioural cycles generated by an endogenous biological clock, the suprachiasmatic nucleus. The circadian system influences the majority of physiological processes, including sleep-wake homeostasis. Impaired sleep and alertness are common symptoms of neurodegenerative disorders, and circadian dysfunction might exacerbate the disease process. The pathophysiology of sleep-wake disturbances in these disorders remains largely unknown, and is presumably multifactorial. Circadian rhythm dysfunction is often observed in patients with Alzheimer disease, in whom it has a major impact on quality of life and represents one of the most important factors leading to institutionalization of patients. Similarly, sleep and circadian problems represent common nonmotor features of Parkinson disease and Huntington disease. Clinical studies and experiments in animal models of neurodegenerative disorders have revealed the progressive nature of circadian dysfunction throughout the course of neurodegeneration, and suggest strategies for the restoration of circadian rhythmicity involving behavioural and pharmacological interventions that target the sleep-wake cycle. In this Review, we discuss the role of the circadian system in the regulation of the sleep-wake cycle, and outline the implications of disrupted circadian timekeeping in neurodegenerative diseases.
    Nature Reviews Neurology 11/2014; DOI:10.1038/nrneurol.2014.206 · 14.10 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Melatonin is the hormone produced by the pineal gland known to regulate physiologic rhythms and to display immunomodulatory and neuroprotective properties. It has been reported that Alzheimer disease patients show impaired melatonin production and altered expression of the 2 G protein-coupled melatonin receptors (MTRs), MT1 and MT2, but the underlying mechanisms are not known. Here we evaluated whether this dysfunction of the melatonergic system is directly caused by amyloid β peptides (Aβ1-40 and Aβ1-42). Aβ treatment of rat pineal glands elicited an inflammatory response within the gland, evidenced by the up-regulation of 52 inflammatory genes, and decreased the production of melatonin up to 75% compared to vehicle-treated glands. Blocking NF-κB activity prevented this effect. Exposure of HEK293 cells stably expressing recombinant MT1 or MT2 receptors to Aβ lead to a 40% reduction in [(125)I]iodomelatonin binding to MT1. ERK1/2 activation triggered by MTRs, but not by the β2-adrenergic receptor, was markedly impaired by Aβ in HEK293 transfected cells, as well as in primary rat endothelial cells expressing endogenous MTRs. Our data reveal the melatonergic system as a new target of Aβ, opening new perspectives to Alzheimer disease diagnosis and therapeutic intervention.-Cecon, E., Chen, M., Marçola, M., Fernandes, P. A. C., Jockers, R., Markus, R. P. Amyloid β peptide directly impairs pineal gland melatonin synthesis and melatonin receptor signaling through the ERK pathway. © FASEB.
    The FASEB Journal 03/2015; DOI:10.1096/fj.14-265678 · 5.48 Impact Factor

Preview (2 Sources)

Available from